Critics argue that modern mass tort litigation has increasingly become a system optimized for speed and volume rather than fairness or accuracy, with procedural tactics that benefit attorneys and early-settling defendants over individual plaintiffs who pursue cases to trial. This criticism centers on consolidated cases like the opioid multidistrict litigation, where tens of thousands of claims were funneled through a single judge under aggressive settlement deadlines, creating enormous pressure to accept pennies-on-the-dollar offers rather than risk jury trials. The concern isn’t that mass torts exist—they serve a legitimate purpose in addressing widespread injuries—but that the machinery itself has been engineered in ways that game the system toward predetermined outcomes.
Plaintiffs’ attorneys and defense counsel have developed sophisticated strategies to move cases through the system faster and with more certainty. Forum shopping, where cases are strategically filed in jurisdictions known for plaintiff-friendly or defense-friendly rulings, creates an incentive structure that rewards venue manipulation over merit. Proceduralists have noted that the MDL (multidistrict litigation) system, designed to streamline handling of similar cases, has evolved into a parallel legal universe with its own rules, pressures, and outcomes that often diverge sharply from what would happen in individual trials scattered across the country.
Table of Contents
- How Do Plaintiffs’ Attorneys Steer Cases Toward Settlements?
- The MDL System’s Built-In Pressures Toward Settlement
- Early Settlement Pressure and the Liquidated Damages Problem
- How Contingency Fees Misalign Incentives
- Strategic Use of Bellwether Trials to Force Settlement
- The Hidden Costs of Rapid Claim Administration
- Real-World Gaming: The Opioid Settlement Structure
- Frequently Asked Questions
How Do Plaintiffs’ Attorneys Steer Cases Toward Settlements?
Forum shopping remains one of the most visible criticisms leveled at mass tort attorneys. Rather than letting cases proceed where the defendant is located or where injury occurred, plaintiffs’ counsel file in jurisdictions with jury verdicts that lean plaintiff-favorable or judges with reputations for approving large class settlements. The talc litigation against johnson & Johnson saw cases filed predominantly in New Jersey and other jurisdictions, then consolidated into an MDL in New Jersey federal court—a venue that some critics argue was selected precisely because of jury tendencies and judicial leanings rather than due process. This creates a structural incentive to litigate geography rather than facts.
Plaintiff steering—the process of selecting which injured people become named plaintiffs or receive priority in settlement distributions—introduces another pressure point. Not all claimants have equal injury profiles, and some are far more sympathetic or valuable than others at trial. By selecting sympathetic plaintiffs for early visibility and marginalizing others, mass tort attorneys can shape the narrative and leverage jury pressure into early settlement offers. A plaintiff with clear causation and severe injury becomes the public face of the case, while thousands of claimants with borderline injuries or disputed causation remain anonymous and pressured to accept quick settlements.
The MDL System’s Built-In Pressures Toward Settlement
The multidistrict litigation framework, while intended to manage duplicative cases efficiently, creates structural incentives that can work against plaintiffs’ individual interests. MDL judges have tremendous power—they set bellwether trial dates, control discovery, and preside over global settlement negotiations—and their caseload pressures create subtle but powerful incentives to move cases toward resolution rather than trial. A judge managing 20,000 opioid claims faces vastly different operational pressures than a judge handling ten individual cases; the scale itself becomes a pressure valve toward settlement. Defendants also benefit from MDL structures in ways critics highlight.
Instead of facing hundreds of individual juries across the country, a defendant faces one judge and one set of rules. This consolidation reduces variance and uncertainty—which is actually better for justice in some respects but creates predictability that defendants can exploit. Major pharmaceutical and industrial defendants now actively welcome MDLs because the outcome becomes manageable and the total exposure can be capped, whereas fifty separate trials across fifty jurisdictions creates uncontrollable risk. The asymmetry is real: plaintiffs wanted consolidation to share information and resources, but the system evolved to favor the side with deeper pockets and institutional knowledge of how MDLs actually work.
Early Settlement Pressure and the Liquidated Damages Problem
Global settlement agreements in mass torts often impose tight deadlines for individual plaintiffs to either accept a predetermined payout or opt out and face the costs of solo litigation. The opioid MDL imposed settlement windows of just weeks or months, forcing claimants to make career-altering decisions on compressed timelines. This pressure is especially acute for people injured by defective drugs or devices—they’re often in pain, facing medical bills, and have limited resources to hire their own counsel if they reject the mass settlement offer. The announced settlement amount ($26 billion in the opioid case) sounds enormous, but divided among 100,000+ claimants and paid over years, individual payouts often fall short of actual economic losses for serious cases.
The liquidation tables embedded in many mass settlement agreements are themselves subject to criticism. These tables assign payout values based on factors like injury type or causation strength, but they’re often negotiated behind closed doors between defense counsel, plaintiffs’ counsel, and judges—without individual claimants present. A claimant assigned to a lower payout tier based on the liquidation table has limited recourse to challenge that assignment. This creates a secondary market for litigation outcomes that critics argue prioritizes administrative simplicity over individualized fairness.
How Contingency Fees Misalign Incentives
Plaintiffs’ attorneys typically work on contingency in mass torts, earning a percentage of any recovery. In a case where plaintiffs’ counsel negotiates a global settlement of $100 million, the attorneys might recover $25–30 million in fees. This creates an incentive structure where attorneys benefit enormously from a fast settlement, even if that settlement undervalues individual claims. A case that takes five years to resolve versus ten years means five additional years of cost and risk for the firm—strong motivation to settle early.
Contrast this with a scenario where an individual plaintiff hires counsel on contingency for a solo trial. That attorney also profits from speed, but they face reputational risk and future client loss if they’re known to shortchange claimants. In mass torts, plaintiffs’ counsel negotiates collectively and has already secured a relationship with the plaintiffs’ steering committee; individual disgruntled claimants rarely translate to lost future business. This misalignment is particularly acute in cases where injury is diffuse or difficult to quantify. Attorneys can justify lower payouts by pointing to uncertainty, even when that uncertainty is partly an artifact of how the litigation was structured.
Strategic Use of Bellwether Trials to Force Settlement
Defendants and some plaintiffs’ counsel use bellwether trials—early, representative trials chosen to gauge jury response—as tools to pressure broader settlement. If the first few bellwether trials result in plaintiff verdicts, settlement negotiations accelerate with defendants offering more. If defendants win bellwethers, the opposite pressure applies and plaintiffs’ counsel faces pressure from the broader claimant base to accept lower offers. Critics argue this is rational from a business perspective but distorts the fact-finding process; bellwether outcomes become self-fulfilling prophecies that drive mass outcomes rather than serve as neutral information.
The selection of bellwether cases itself can be gamed. Choosing the most sympathetic plaintiffs and strongest facts for early trial creates a biased signal that influences settlement negotiations. Defense counsel is aware of this and factors it into strategy accordingly. The real problem emerges when bellwether results that reflect cherry-picked facts become the basis for pressuring thousands of claimants with weaker or more complex cases to accept settlements below what full individual trials might have produced.
The Hidden Costs of Rapid Claim Administration
Once a mass settlement is approved, claims administration becomes a critical control point. Settling defendants often hire third-party administrators to process and pay claims, and these administrators have strong financial incentives to deny or minimize claims to reduce total payout exposure. A claimant who submitted documentation for a talc-exposure injury must convince an administrator that the claim meets the liquidation table criteria; if denied, the claimant’s only recourse is an expensive appeal. Many injured people never pursue appeals because the cost and burden exceed the potential recovery.
The speed of claim administration also matters. Early claimants who file immediately often receive higher payouts than late claimants because settlement funds are typically depleted or reduced over time. This creates a perverse incentive for injured people to rush through medical verification and documentation, sacrificing accuracy for speed. Someone dealing with mesothelioma or a chronic illness may not yet know the full scope of their injury; settling early locks them into a fixed payout regardless of how their condition deteriorates.
Real-World Gaming: The Opioid Settlement Structure
The $26 billion national opioid settlement illustrates many of these gaming dynamics in practice. Defendants agreed to pay, but the funds are distributed over eighteen years, meaning actual annual payments to states and injured parties are roughly $1–2 billion per year—a fraction of the opioid epidemic’s economic and human toll. Individual plaintiffs who were injured by opioids but lived in a state that rejected the settlement or pursued separate litigation faced radically different outcomes than those in participating states. Some states negotiated higher per-capita shares, while others received minimal allocations based on population formulas that didn’t account for actual opioid-related deaths or addiction rates.
Within states, claimants faced additional friction. Many states designated only a subset of opioid injuries as eligible for compensation—acute overdose deaths, but not chronic addiction without overdose; pain pill dependence, but not heroin addiction. These categorical exclusions, embedded in settlement language, meant that many people harmed by the opioid supply had no claim at all. A young adult who spent years in addiction and incurred massive treatment costs but never overdosed might receive nothing, while a relative of someone who died received a fixed death benefit negotiated by state attorneys general rather than juries. The settlement process, while efficient from an administrative standpoint, locked in these categorical judgments permanently.
Frequently Asked Questions
Are plaintiffs harmed by mass tort consolidation?
Many plaintiffs benefit from consolidated information-sharing and reduced litigation costs, but others are pressured into quick settlements worth less than individualized trials might yield. The harm depends on the specific case structure and individual claim value.
Can a claimant opt out of a mass settlement?
Yes, most mass settlements allow opt-outs, but opting out means pursuing solo litigation at full personal cost, which is often prohibitively expensive. The practical choice is rarely equal between accepting the offered settlement and walking away.
Who sets the payout amounts in mass settlements?
Settlement payout structures are negotiated between defense counsel, plaintiffs’ counsel, and sometimes the presiding MDL judge. Individual claimants rarely have direct input, though some settlements now include claims objection processes.
Why do defendants agree to large mass settlements?
Large settlements cap total exposure and eliminate venue uncertainty. A defendant might pay more in a lump settlement than in a few trials but less than the sum of many individual jury verdicts across different states, making settlement economically rational.
How long does a claimant have to decide whether to accept a settlement?
Settlement windows vary but often range from weeks to a few months. Claimants who miss the deadline are typically barred from participating in the settlement and must pursue independent litigation.
What happens to unclaimed settlement funds?
Leftover funds are typically distributed among participating states or, in some cases, returned to defendants. A small percentage of settled cases remain unclaimed, meaning some injured people never access compensation even though a settlement existed.